Cyclin-dependent kinase inhibitor p27(kip1) is expressed at high levels in cells that express a myelinating phenotype

Journal of Neuroscience Research

Volumn 50, Issue 3, 1997, Pages 373-382

  Friessen, Andrew J ^a   Miskimins, W Keith ^a   Miskimins, Robin ^a  

^a W O Farber Center for Civic Leadership   (United States)

Author keywords

CAMP; Cell cycle; Cyclin; Oligodendrocytes; p27

Indexed keywords

CYCLIC AMP; CYCLIN DEPENDENT KINASE INHIBITOR;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; ENZYME INHIBITION; GENE EXPRESSION REGULATION; MYELINATION; NERVE CELL DIFFERENTIATION; NONHUMAN; OLIGODENDROGLIA; PHENOTYPE; PRIORITY JOURNAL; SCHWANN CELL; STEM CELL;

1-METHYL-3-ISOBUTYLXANTHINE; ANIMALS; BRAIN; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE; CELLS, CULTURED; CYCLIC AMP; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; KINETICS; MICROTUBULE-ASSOCIATED PROTEINS; MYELIN BASIC PROTEINS; OLIGODENDROGLIA; PHENOTYPE; RATS; RATS, SPRAGUE-DAWLEY; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 0030700880     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4547(19971101)50:3<373::AID-JNR3>3.0.CO;2-F     Document Type: Article

References (43)

1. Andres V, Walsh K (1996): Myogenin expression, cell cycle withdrawal, and phenotypic differentiation are temporally separable events that precede cell fusion upon myogenesis. J Cell Biol 132:657-666.
2. Bansal R, Pfeiffer SE (1987): J Neurochem 49:1902-1911.
3. Berti-Mattera LN, Larocca JN, Pellegrino de Iraldi A, Pasquini JM, Soto EF (1984): Isolation of oligodendroglial cells from young and adult whole rat brains using an in situ generated Percoll density gradient. Neurochem Int 6:41-50.
4. Buckingham M (1992): Making muscle in mammals. Trends Genet 8:144-149.
5. deSouza NJ, Dohadwalla AN, Reden J (1983): Forskolin: A labdane diterpenoid with antihypertensive, positive ionotropic, platelet aggregation inhibitory and adenylate cyclase activating properties. Med Res Rev 3:201-219.
6. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer E, Kinzler KW, Vogelstein B (1993): WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
7. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Winman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW, Vogelstein B (1994): WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54:1169-1174.
8. Elledge SJ (1996): Cell cycle checkpoints: Preventing an identity crisis. Science 274:1664-1672.
9. Emerson CP Jr (1990): Myogenesis and developmental control genes. Curr Opin Cell Biol 2:1065-1075.
10. kip1-deficient mice. Cell 85:733-744.
11. Gandelman K-Y, Pfeiffer SE, Carson JH (1989): Cyclic AMP regulation of P0 glycoprotein and myelin basic protein gene expression in semi-differentiated peripheral neurinoma cell line D6P2T. Development 106:389-398.
12. Gard AL, Pfeiffer SE (1989): Oligodendrocyte progenitors isolated directly from developing telencephalon at a specific phenotypic stage: Myelinogenic potential in a defined environment. Development 106:119-132.
13. -) under different mitogenic control. Neuron 5:615-625.
14. Gu Y, Turck CW, Morgan DO (1993): Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366:707-710.
15. Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, Beach D, Lassar A (1995): Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267:1018-1021.
16. Hall M, Bates S, Peters G (1995): Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 11:1581-1588.
17. 1 cyclin-dependent kinases. Cell 75:805-816.
18. kip1) ot cyclin-dependent kinase 4 activation. Cell 79:487-496.
19. Kimhy Y, Spector I, Barak Y, Littauer UZ (1976): Maturation of neuroblastoma cells in the presence of dimethylsulfoxide. Proc Natl Acad Sci USA 73:462-466.
20. kip1. Cell 85:721-732.
21. Koff A, Ohtsuki M, Polyak K, Roberts JM, Massague J (1993): Negative regulation of G1 in mammalian cells: Inhibition of cyclin E-dependent kinase by TGF-β. Science 260:536-539.
22. Kranenburg O, Scharnhorst V, Van der Eb AJ, Zantema A (1995): Inhibition of cyclin-dependent kinase activity triggers neuronal differentiation of mouse neuroblastoma cells. J Cell Biol 131:227-234.
23. kip2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9:639-649.
24. kip2, a structurally distinct member of the Cip1 cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9:650-622.
25. kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85:707-720.
26. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR (1994): Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211:90-98.
27. Olson EN (1992): Interplay between proliferation and differentiation within the myogenic lineage. Dev Biol 154:261-272.
28. Olson EN, Klein WH (1994): bHLH factors in muscle development: Dead lines and commitments, what to leave in and what to leave out. Genes Dev 8:1-8.
29. Pagano M, Tam SW, Theodiras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M (1995): Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682-685.
30. cip1 in muscle and other terminally differentiating cells. Science 267:1024-1027.
31. kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 8:9-22.
32. kip1, a cyclin-cdk inhibitor and potential mediator of extracellular antimitogenic signals. Cell 78:59-66.
33. Raible DW, McMorris FA (1989): Cyclic AMP regulates the rate of differentiation of oligodendrocytes without changing the lineage commitment of their progenitors. Dev Biol 133:437-446.
34. Raible DW, McMorris FA (1993): Oligodendrocyte differentiation and progenitor cell proliferation are independently regulated by cyclic AMP. J Neurosci Res 34:287-294.
35. Reynisdottir I, Polyak K, Iavarone A, Massague J (1995): Kip/Cip and Ink4 cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev 9:1831-1845.
36. 1 stage of the cell cycle and overrides constitutive r-myc expression. Mol Cell Biol 12:2351-2358.
37. kip1. Cancer Res 56:1389-1399.
38. 1 cyclin-dependent kinases. Genes Dev 9:1149-1163.
39. Slingerlund JM, Hengst L, Pan CH, Alexander D, Stampfer MF, Reed SI (1994): A novel inhibitor of cyclin-cdk activity detected in transforming growth factor β-arrested epithelial cells. Mol Cell Biol 14:3683-3694.
40. Toyoshima H, Hunter T (1994): p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 78:67-74.
41. Weintraub H, Davis R, Tapscott S, Thayer M, Krause M, Benezra R, Blackwell TK, Turner D, Rupp R, Hollenberg S, Zhuang Y, Lassar A (1991): The myoD gene family: Nodal point during specification of the muscle cell lineage. Science 251:761-766.
42. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D (1993): p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704.
43. Zhang X, Miskimins R (1993): Binding at an NFI site is modulated by cyclic AMP-dependent activation of myelin basic protein gene expression. J Neurochem 60:2010-2017.